Pfizer Inc - PFE Earnings per share for the last 12 months

Public company logo of Pfizer Corporation (PFE)

Following the decline in vaccine demand, Pfizer Inc. (PFE) is focusing on oncology and new assets. A powerful team of scientists with premium funding serves as the pillar of growth. The year-over-year change in EPS (TTM) visualizes this trend, where the value -59.10 acts as the target level. However, international profits remain vulnerable due to geopolitical risks and logistical disruptions in raw material supplies.

PFE Pfizer Inc: Earnings per share for the last twelve months in the range 02/11/2024 - 11/12/2026

PFE (Pfizer Corporation): analytical breakdowns and indicator data

- share price and expert price forecast:
Price Chart pfizer.com|PFE - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization Pfizer Inc|PFE - Enterprise Value
- book capitalization indicators:
Net Assets per Share Pfizer|PFE - Company Book Value|Capitalization to Book Value Ratio pfizer.com|PFE - Company Total Assets
- company total debt and liquidity indicators:
Debt to Capital Ratio Pfizer Inc.|PFE - Long-Term Debt to Equity|Current Liabilities to Equity Pfizer Corp|PFE - Company Aggregate Debts|Debts to Book Capitalization Ratio Pfizer Inc|PFE - Company Long-Term Debts|Short-Term Debt Volume Pfizer|Critical Liquidity Ratio pfizer.com
- business earnings and investment ratios data:
PFE - Net Profit|Expected Net Profit Pfizer Inc.|PFE - Price to Earnings Ratio|Future Price to Earnings Multiple Pfizer Inc|PFE - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Pfizer Inc|PFE - Operating profit EBITDA|Net earnings per share for the last four quarters Pfizer|PFE - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months pfizer.com|PFE - Earnings growth in current year|Expected earnings per share growth for next year Pfizer Inc.
Fundamental company valuation:pfizer.com
Signature product of Pfizer Inc

Investors are assessing the fundamental resilience of Pfizer Inc. (PFE) through the stability of its earnings per share. Geopolitical instability and vaccine logistics disruptions could significantly constrain these growth rates. By analyzing the historical EPS YoY TTM delta, the user observes smoothed revenue dynamics that neutralize the difference between GAAP and Non-GAAP standards. This asset requires a balance between current yield and volatility risk.

Competitor analysis for Pfizer Inc.

LLY: Earnings per share for the last twelve months|ABBV: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months AZN|NVS (Novartis Inc.) - Net earnings per share (EPS TTM)|MSD (MRK) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Novo Nordisk A/S (NVO)|amgen.com - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) SNY (Sanofi S.A.)|Net earnings per share for the trailing year Bristol Myers Squibb Company|GSK - Earnings per share for the last twelve months|Earnings per one share for the last 12 months TAK|TEVA: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months RDY (drreddys.com)|VTRS (Viatris) - Net earnings per share (EPS TTM)|Roivant (ROIV) - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months ZLAB (Zai Lab Ltd.)|BHC: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) COSM (Cosmos Health Inc.)